Adverse events post smallpox-vaccination: Insights from tail scarification infection in mice with vaccinia virus

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Mota, Bruno E F ^a   Gallardo Romero, Nadia ^b   Trindade, Giliane ^a   Keckler, M Shannon ^b   Karem, Kevin ^b   Carroll, Darin ^b   Campos, Marco A ^c   Vieira, Leda Q ^a   da Fonseca, Flávio G ^a   Ferreira, Paulo C P ^a   Bonjardim, Cláudio A ^a   Damon, Inger K ^b   Kroon, Erna G ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 23; TUMOR NECROSIS FACTOR ALPHA; VACCINIA ANTIBODY; AUTACOID; CYTOKINE; HOMEODOMAIN PROTEIN; RAG 1 PROTEIN; RAG-1 PROTEIN;

ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; HOST RESISTANCE; INOCULATION; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; NUDE MOUSE; POXVIRUS INFECTION; SCAR FORMATION; VACCINIA VIRUS; VIRAL CLEARANCE; VIRUS REPLICATION; VIRUS TRANSMISSION; WILD TYPE; ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; C57BL MOUSE; CELL LINE; IMMUNOLOGY; KINETICS; LYMPHOCYTE DEPLETION; METABOLISM; MORTALITY; PHYSIOLOGY; RABBIT; SMALLPOX; TAIL; VACCINATION; VACCINIA; VIROLOGY;

ANIMALIA; MURINAE; MUS; ORYCTOLAGUS CUNICULUS; POXVIRIDAE; VACCINIA VIRUS; VARIOLA VIRUS;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOKINES; HOMEODOMAIN PROTEINS; INFLAMMATION MEDIATORS; KINETICS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; ORGAN SPECIFICITY; RABBITS; SMALLPOX; TAIL; VACCINATION; VACCINIA; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 79954538830     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018924     Document Type: Article

References (42)

1. Moss B, (2001) Poxviridae: The viruses and their replication. Fundamental Virology. Forth Edition ed: Lippincott Williams & Wilkins.
2. Fenner FHD, Arita I, Jezek Z, Ladnyi I, (1988) Smallpox and its eradication. Geneva World Health Organization.
3. Bray M, Wright ME, (2003) Progressive vaccinia. Clin Infect Dis 36: 766-774.
4. Edghill-Smith Y, Golding H, Manischewitz J, King LR, Scott D, et al. (2005) Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11: 740-747.
5. Saito T, Fujii T, Kanatani Y, Saijo M, Morikawa S, et al. (2009) Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA 301: 1025-1033.
6. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, et al. (2003) Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A 100: 9458-9463.
7. Liu L, Zhong Q, Tian T, Dubin K, Athale SK, et al. (2010) Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med 16: 224-227.
8. Fang M, Sigal LJ, (2005) Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus. J Immunol 175: 6829-6836.
9. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA, (2003) Smallpox vaccination: a review, part II. Adverse events. Clin Infect Dis 37: 251-271.
10. Melamed S, Paran N, Katz L, Ben-Nathan D, Israely T, et al. (2007) Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice. Vaccine 25: 7743-7753.
11. Freyschmidt EJ, Mathias CB, MacArthur DH, Laouar A, Narasimhaswamy M, et al. (2007) Skin inflammation in RelB(-/-) mice leads to defective immunity and impaired clearance of vaccinia virus. J Allergy Clin Immunol 119: 671-679.
12. Tian T, Liu L, Freyschmidt EJ, Murphy GF, Kupper TS, et al. (2009) Overexpression of IL-1alpha in skin differentially modulates the immune response to scarification with vaccinia virus. J Invest Dermatol 129: 70-78.
13. Kawakami Y, Tomimori Y, Yumoto K, Hasegawa S, Ando T, et al. (2009) Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J Exp Med 206: 1219-1225.
14. Howell MD, Gallo RL, Boguniewicz M, Jones JF, Wong C, et al. (2006) Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 24: 341-348.
15. Xu R, Johnson AJ, Liggitt D, Bevan MJ, (2004) Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 172: 6265-6271.
16. Chaudhri G, Panchanathan V, Bluethmann H, Karupiah G, (2006) Obligatory requirement for antibody in recovery from a primary poxvirus infection. J Virol 80: 6339-6344.
17. Ramirez JC, Tapia E, Esteban M, (2002) Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J Gen Virol 83: 1059-1067.
18. Worthington M, (2003) Role of antibody in recovery from severe vaccinia virus infection. Clin Infect Dis 37: 864 865 author reply 865-866.
19. Mortimer PP, (2003) Anticipating smallpox as a bioterrorist weapon. Clin Med 3: 255-259.
20. Vorou RM, Papavassiliou VG, Pierroutsakos IN, (2008) Cowpox virus infection: an emerging health threat. Curr Opin Infect Dis 21: 153-156.
21. Parker S, Nuara A, Buller RM, Schultz DA, (2007) Human monkeypox: an emerging zoonotic disease. Future Microbiol 2: 17-34.
22. Spriggs MK, Koller BH, Sato T, Morrissey PJ, Fanslow WC, et al. (1992) Beta 2-microglobulin-, CD8+ T-cell-deficient mice survive inoculation with high doses of vaccinia virus and exhibit altered IgG responses. Proc Natl Acad Sci U S A 89: 6070-6074.
23. Gherardi MM, Ramirez JC, Esteban M, (2003) IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J Gen Virol 84: 1961-1972.
24. Kohyama S, Ohno S, Isoda A, Moriya O, Belladonna ML, et al. (2007) IL-23 enhances host defense against vaccinia virus infection via a mechanism partly involving IL-17. J Immunol 179: 3917-3925.
25. Puissant-Lubrano B, Bossi P, Gay F, Crance JM, Bonduelle O, et al. (2010) Control of vaccinia virus skin lesions by long-term-maintained IFN-gamma+TNF-alpha+ effector/memory CD4+ lymphocytes in humans. J Clin Invest 120: 1636-1644.
26. Sakala IG, Chaudhri G, Buller RM, Nuara AA, Bai H, et al. (2007) Poxvirus-encoded gamma interferon binding protein dampens the host immune response to infection. J Virol 81: 3346-3353.
27. Harris N, Buller RM, Karupiah G, (1995) Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J Virol 69: 910-915.
28. Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C, et al. (1993) Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 261: 1445-1448.
29. Rolph MS, Ramshaw IA, Rockett KA, Ruby J, Cowden WB, (1996) Nitric oxide production is increased during murine vaccinia virus infection, but may not be essential for virus clearance. Virology 217: 470-477.
30. Kohno K, Kurimoto M, (1998) Interleukin 18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both. Clin Immunol Immunopathol 86: 11-15.
31. Perera LP, Goldman CK, Waldmann TA, (2001) Comparative assessment of virulence of recombinant vaccinia viruses expressing IL-2 and IL-15 in immunodeficient mice. Proc Natl Acad Sci U S A 98: 5146-5151.
32. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, et al. (1992) RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68: 869-877.
33. Panchanathan V, Chaudhri G, Karupiah G, (2006) Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function. J Virol 80: 6333-6338.
34. Lustig S, Maik-Rachline G, Paran N, Melamed S, Israely T, et al. (2009) Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response. Vaccine 27: 1691-1699.
35. Brundler MA, Aichele P, Bachmann M, Kitamura D, Rajewsky K, et al. (1996) Immunity to viruses in B cell-deficient mice: influence of antibodies on virus persistence and on T cell memory. Eur J Immunol 26: 2257-2262.
36. Esteban DJ, Buller RM, (2005) Ectromelia virus: the causative agent of mousepox. J Gen Virol 86: 2645-2659.
37. Pantelouris EM, (1968) Absence of thymus in a mouse mutant. Nature 217: 370-371.
38. Neyts J, Leyssen P, Verbeken E, De Clercq E, (2004) Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob Agents Chemother 48: 2267-2273.
39. Sette A, Moutaftsi M, Moyron-Quiroz J, McCausland MM, Davies DH, et al. (2008) Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 28: 847-858.
40. Xu RH, Remakus S, Ma X, Roscoe F, Sigal LJ, (2010) Direct presentation is sufficient for an efficient anti-viral CD8+ T cell response. PLoS Pathog 6: e1000768.
41. Orr N, Forman M, Marcus H, Lustig S, Paran N, et al. (2004) Clinical and immune responses after revaccination of israeli adults with the Lister strain of vaccinia virus. J Infect Dis 190: 1295-1302.
42. Mota BE, Trindade GS, Diniz TC, da Silva-Nunes M, Braga EM, et al. (2010) Seroprevalence of orthopoxvirus in an Amazonian rural village, Acre, Brazil. Arch Virol 155: 1139-1144.